Evidence map›Paper›PMID 42012179›Full record

ArticleJournal of virology2026

Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.

Soner Yildiz, Sara S El Zahed, Fernando Villalón-Letelier, Qian Wang, Sowmya Yelleswarapu, Gloria Dawodu, Kaijun Jiang, Raveen Rathnasinghe, Umut Karakus, Rocio Seoane and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Soner YildizDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-7235-6108
Sara S El ZahedDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fernando Villalón-LetelierDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Qian WangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sowmya YelleswarapuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gloria DawoduDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kaijun JiangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Umut KarakusDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-6392-7765
Rocio SeoaneDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sara Cuadrado-CastanoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-6551-1827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza A viruses (IAVs) lacking the nonstructural protein 1 (NS1) gene (IAV-ΔNS1) are attenuated both IMPORTANCE: IAV-ΔNS1 vectors are promising vaccine platforms that elicit strong immune responses with a good safety profile. However, integration of immune-stimulatory cytokines into vector design to boost immunogenicity has been technically challenging. In this study, we developed a genetically re-engineered segment 8 design that overcomes prior limitations due to design complexity or vector efficiency, enabling high-level expression of the transgene, i.e., human interleukin 2 and other diverse proteins. The platform retains strong replicative capacity in permissive systems and remains genetically stable, making it suitable for scalable vaccine or therapeutic development. By improving both the flexibility and functionality of IAV-ΔNS1 vectors, our work advances the utility of influenza A viruses as customizable tools for vaccine delivery, immune modulation, and therapeutic applications.

Indexed as

Genetic VectorsInfluenza A virusAnimalsDogsFemaleHumansInfluenza VaccinesInterleukin-2Madin Darby Canine Kidney CellsMiceTransgenesVaccines, AttenuatedViral Nonstructural ProteinsVirus ReplicationInfluenza VaccinesINS1 protein, influenza virusInterleukin-2Vaccines, AttenuatedViral Nonstructural ProteinsIL-15IL-2influenza A virussecretory protein deliveryΔNS1 vectors

Identifiers

PMID42012179
PMCPMC13185603

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.